GC Therapeutics (GCTx), a pioneering biotechnology company advancing the next generation of cell-based medicines through its TFome^TM (Transcription-Factor-ome) induced pluripotent stem cell (iPSC) programming platform that enables expansion into in vivo rejuvenation and reprogramming, today announced the appointment of Stefan Irion, MD,  as chief scientific officer.

GC Therapeutics, Inc. (GCTx), a biotechnology company created to scale and unlock the next generation of cell therapy-based medicines through its TFome™ cellular programming platform, today announced a series of corporate and pipeline updates.

GC Therapeutics (GCTx), a biotechnology company with the mission to enable scalable, low-cost, and accessible human cell therapies for all patients, today announced a major advance in cell programming through the systematic, empirical exploration of transcription factor (TF) combinations to drive cell fates.

GC Therapeutics (GCTx), a pioneering biotechnology company advancing groundbreaking iPSC-based cell therapies, today announced the appointment of two industry leaders to its executive team.

A new cell therapy company takes its vision from four founders, and its skin from George Church

GC Therapeutics, a biotech startup that is writing the recipe book for turning a stem cell into nearly any natural human cell, formally launched Thursday

GC Therapeutics has Church’s initials, a 4-day cell differentiation platform, and $65 million

Renowned Harvard geneticist and serial entrepreneur George Church is at it again, with a venture that has raised $75 million from investors.

TFome™, the world’s first “plug-and-play” iPSC cellular programming platform, streamlines development and accelerates pipeline of potential best-in-class cell therapies across diverse therapeutic areas 

“Our technology allows us to discover novel cell-differentiation recipes and make practically any cell type in the body, including those that have not been made before,” said Alex Ng, co-first author with Parastoo Khoshakhlagh

GCTx founders co-authored with other distinguished US and international scientists "A comprehensive library of human transcription factors for cell fate engineering" published in the November 2020 issue of Nature Biotechnology

Harvard Medical School describes how GCTx is tackling COVID-19 utilizing our TFome cell engineering technology

Biogen awarded GCTx Golden Tickets, which provide lab space at Lab Central

CBS 60 Minutes featured our synthetic biology-based cell therapy platform technology

Amgen awarded GCTx Golden Tickets, which provide lab space at Lab Central (Cambridge, MA) and access to Amgen’s expertise in drug development

One year, 1 lab, 16 spinouts. Nature Biotechnology featured GCTx as a successful startup

YEi Start in France is an accelerator program for science-based startup companies

“The people who want to change the world are people who want to keep moving,” said Harvard President Lawrence Bacow during the ceremony

“The teams competing in this year’s President’s Innovation Challenge (PIC) represent the extraordinary talent that exists across the University,” said Harvard President Lawrence Bacow GCTx: Revolutionizing cell therapy by building a cell engineering platform that is 100 times faster and 10 times more efficient, enabling customized therapeutics tailored to target hard-to-cure diseases

Award recognizes TFome platform technology that enables rapid engineering of a broad spectrum of tissue-specific cell types